A Randomized, Sham-Procedure-Controlled Trial of Percutaneous Myocardial Laser Therapy
  • Jan Erik Nordrehaug
  • Janet M. Fauls


A majority of patients with angina related to coronary artery disease respond to medical management, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG). There is, however, a growing number of patients who have medically refractory angina caused by diffuse coronary artery disease who are not eligible for PCI or CABG owing to diffuse, distal disease.1 Treatment options are limited for this subset of patients.


Percutaneous Coronary Intervention Coronary Artery Bypass Grafting Sham Group Placebo Effect Chronic Total Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Muhkerjee, D., Bhatt, D., Roe, T., et al. 1999. Direct myocardial revascularization and angiogenesis—how many patients might be eligible? Am. J. Cardiol. 84:598–600.CrossRefGoogle Scholar
  2. 2.
    Wiseth, R., Korfang, K., Ilebekk, A., et al. 2001. Myocardial laser revascularization in the year 2000 as seen by a Norwegian specialist panel. The process of evaluating and implementing new methods in clinical practice. Scand. Cardiovasc. J. 35:14–18.CrossRefGoogle Scholar
  3. 3.
    Oesterle, S. N., Sanborn, T. A., Ali, N., et al. 2000. Percutaneous transmyocardial laser revascularization for severe angina: the PACIFIC randomised trial. Lancet. 356:1705–1710.CrossRefGoogle Scholar
  4. 4.
    Byerly, H. 1976. Explaining and exploiting placebo effects. Perspect. Biol. Med. 10:423–435.Google Scholar
  5. 5.
    Kim, C. B., Kesten, R., Javier, M., et al. 1997. Percutaneous method of laser transmyocardial revascularization. Cathet. Cardiovasc. Diag. 40:223–228.CrossRefGoogle Scholar
  6. 6.
    Spertus, J. A., Winder, J. A., Dewhurst, T. A., et al. 1995. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J. Am. Coll. Cardiol. 25:333–341.CrossRefGoogle Scholar
  7. 7.
    Wilkoff, B. L., Corey, J., Blackburn, G. 1989. A mathematical model of the cardiac chronotropic response to exercise. J. Electrophysiol. 3:176–180.CrossRefGoogle Scholar
  8. 8.
    Bienenfeld, L., Frishman, W., Glasser, S. P. 1996. The placebo effect in cardiovascular disease. Am. Heart. J. 132:1207–1221.CrossRefGoogle Scholar
  9. 9.
    Glasser, S. P., Clark, P., Lipicky, R., et al. 1991. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA. 265:1550–1554.CrossRefGoogle Scholar
  10. 10.
    Gray, T. J., Burns, S. M., Clarke, S. C., et al. 2003. Percutaneous myocardial laser revascularization in patients with refractory angina pectoris. Am. J. Cardiol. 91:661–666.CrossRefGoogle Scholar
  11. 11.
    Leon, M. B., Baim, D. S., Moses, J. W., et al. 2000. A randomized blinded clinical trial comparing percutaneous laser myocardial revascularization (using Biosense LV mapping) in patients with refractory coronary ischemia. Circulation. 102:II–565.Google Scholar
  12. 12.
    Stone, G. W., Teirstein, P. S., Rubenstein, R., et al. 2002. A prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. J. Am. Coll. Cardiol. 39:1581–1587.CrossRefGoogle Scholar
  13. 13.
    Allen, K. B., Dowling, R. D., Fudge, T. L., et al. 1999. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina. N. Engl. J. Med. 341:1029–1036.CrossRefGoogle Scholar
  14. 14.
    Frazier, O. H., March, R. J., Horvath, K. A. 1999. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary disease. N. Engl. J. Med. 341:1021–1028.CrossRefGoogle Scholar
  15. 15.
    Burkhoff, D., Schmidt, S., Schulman, S. P., et al. 1999. Transmyocardial revascularization compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomized trial. Lancet. 354:885–890.CrossRefGoogle Scholar
  16. 16.
    Schofield, P. M., Sharples, L. D., Caine, N., et al. 1999. Transmyocardial laser revascularization in patients with refractory angina: a randomized controlled trial. Lancet. 353:519–524.CrossRefGoogle Scholar
  17. 17.
    Aaberge, L., Nordstrand, K., Dragsund, M., et al. 2000. Transmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial. J. Am. Coll. Cardiol. 35:1170–1177.CrossRefGoogle Scholar
  18. 18.
    Aaberge, L., Rootwelt, K., Blomhoff, S., et al. 2002. Continued symptomatic improvement three to five years after transmyocardial revascularization with CO2 laser: a late clinical follow-up of the Norwegian randomized trial with transmyocardial revascularization. J. Am. Coll. Cardiol. 39:1588–1593.CrossRefGoogle Scholar
  19. 19.
    Allen, K. B., Dowling, R. D., Angell, W., et al. 2004. Transmyocardial revascularization: five-year follow-up of a prospective, randomized, multicenter trial. Ann. Thorac. Surg. 77:1228–1234.CrossRefGoogle Scholar
  20. 20.
    Gibbons, R., Abrams, J., Chatterjee, K., et al. 2003. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina (summary article): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation. 107:149–158.CrossRefGoogle Scholar
  21. 21.
    Bridges, C. R., Horvath, K. A., Nugent, B., et al. 2004. Society of Thoracic Surgeons Practice Guideline: Transmyocardial Laser Revascularization. Ann. Thorac. Surg. 77:1484–1502.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Jan Erik Nordrehaug
    • 1
  • Janet M. Fauls
    • 2
  1. 1.Department of Heart DiseaseHaukeland University HospitalBergenNorway
  2. 2.Regulatory, Quality, and Clinical AffairsCardioGenesis CorporationFoothill Ranch

Personalised recommendations